A VISION Substudy of Reader Agreement on 68Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177Lu-PSMA-617 Radioligand Therapy - Beyond the Abstract

The pivotal phase 3 VISION study used [68Ga]Ga-PSMA-11 (also known as 68Ga-PSMA-11) imaging to identify patients with metastatic castration-resistant prostate cancer eligible for [177Lu]Lu-PSMA-617 radioligand therapy, based on predefined read criteria. In this substudy of VISION, the inter-reader variability and intra-reader reproducibility of visual assessments of 68Ga-PSMA-11 positron emission tomography scans using the VISION read criteria were evaluated.

Phillip Kuo, MD, PhD, Professor of Medical Imaging, Medicine and Biomedical Engineering, University of Arizona, Tucson, Arizona

Read the Abstract